Spero Therapeutics Inc. (SPRO)
| Bid | 0.81 |
| Market Cap | 44.43M |
| Revenue (ttm) | 96.21M |
| Net Income (ttm) | 3.54M |
| EPS (ttm) | 0.08 |
| PE Ratio (ttm) | 10.19 |
| Forward PE | -1.08 |
| Analyst | Hold |
| Ask | 0.84 |
| Volume | 429,944 |
| Avg. Volume (20D) | 187,951 |
| Open | 0.82 |
| Previous Close | 0.82 |
| Day's Range | 0.80 - 0.92 |
| 52-Week Range | 0.73 - 1.81 |
| Beta | 0.69 |
About SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct actin...
Analyst Forecast
According to 4 analyst ratings, the average rating for SPRO stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 513.50% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK DealSpero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical du...
